Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of inactivated COVID-19 vaccine in adults with HIV infection
ChiCTR2100054393Phase 4Recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inactivated sars-cov-2 vaccine (vero cell) in coronavirus disease 2019 (COVID-19), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Novel coronavirus antibody 4-fold increase rate and antibody level, Incidence of adverse reactions/events within 30 minutes after each dose and 2 more. Started Aug 2021; status: recruiting.
02
Drugs
inactivated sars-cov-2 vaccine (vero cell)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100054393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054393.